A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that down-regulates hepatic low-density lipoprotein receptor (LDLR) by binding and shuttling LDLR to lysosomes for degradation. The development of therapy that inhibits PCSK9 has attracted considerable attention...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Wang, Xuelei, Chen, Xiaofang, Zhang, Xiumin, Su, Chunyan, Yang, Mengxia, He, Wei, Du, Yu, Si, Shuyi, Wang, Li, Hong, Bin
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7026728/
https://ncbi.nlm.nih.gov/pubmed/32058941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102650
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados